Jump to content

Active placebo

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Tom.Reding (talk | contribs) at 19:15, 19 May 2016 (vauthors/veditors or enumerate multiple authors/editors (CS1 maintenance); WP:GenFixes active using AWB). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

An active placebo is a placebo that produces noticeable side effects that may convince the person being treated that they are receiving a legitimate treatment, rather than an ineffective placebo.

Nomenclature

According to a 1965 paper,[1] the term "concealed placebo" (German: Kaschiertes Placebo) was suggested in a 1959 paper published in German.[2]

Example

Morphine and gabapentin are painkillers with the common side effects of sleepiness and dizziness. In a 2005 study assessing the effects of these painkillers on neuropathic pain, Lorazepam was chosen as an active placebo because it is not a painkiller but it does cause sleepiness and can cause dizziness.[3]

Testing from the late 1950s onwards on narcotic analgesics like morphine also has used dicyclomine as an active placebo, and on some occasions it was reported to cause the Straub mouse tail reaction, as do most narcotics. Clonidine is now finding more use as an active placebo for narcotics as well.

References

  1. ^ Park LC, Covi U (April 1965). "Nonblind placebo trial: an exploration of neurotic patients' responses to placebo when its inert content is disclosed" (PDF). Archives of General Psychiatry. 12: 336–45. doi:10.1001/archpsyc.1965.01720340008002. PMID 14258363.
  2. ^ Haas H, Fink H, Haertfelder G (1959). "Das Placeboproblem". Fortschr Arzneimittclforsch (in German). 1: 279–454. PMID 13710190. {{cite journal}}: Unknown parameter |trans_title= ignored (|trans-title= suggested) (help)
  3. ^ Gilron I, Bailey JM, Tu D, Holden RR, Weaver DF, Houlden RL (March 31, 2005). "Morphine, gabapentin, or their combination for neuropathic pain". N Engl J Med. 352 (13): 1324–34. doi:10.1056/NEJMoa042580. PMID 15800228.